Literature DB >> 27928687

Histopathological and radiological reporting in rectal cancer: concepts and controversies, facts and fantasies.

S Balyasnikova1,2,3, N Haboubi4, B Moran5, G Brown1,2,3.   

Abstract

In rectal cancer patients, the stage of the disease, local spread and distant metastases status drive the treatment decisions to be made. Histopathology remains the gold standard, but preoperative staging, particularly magnetic resonance imaging (MRI), is pivotal for defining surgical planes and finding patients who could potentially benefit from preoperative regimes. Unfortunately, due to a lack of awareness, expertise and practise the quality of rectal cancer MRI and histopathology reporting varies among centres. This paper highlights the most important and frequently occurring radiological and histopathological discrepancies/mistakes to be aware of.

Entities:  

Keywords:  Histopathological reporting; MRI staging; Rectal cancer

Mesh:

Year:  2016        PMID: 27928687     DOI: 10.1007/s10151-016-1555-y

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  34 in total

1.  Magnetic resonance imaging-detected lymph nodes close to the mesorectal fascia are rarely a cause of margin involvement after total mesorectal excision.

Authors:  O C Shihab; P Quirke; R J Heald; B J Moran; G Brown
Journal:  Br J Surg       Date:  2010-09       Impact factor: 6.939

2.  Are we accurately measuring the depth of the submucosal invasion in early colorectal cancer by equating the Kikuchi submucosa levels with distances measured in fractions of a millimetre?

Authors:  Najib Haboubi; Emil Salmo
Journal:  Colorectal Dis       Date:  2013-07       Impact factor: 3.788

3.  Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG).

Authors:  M R S Siddiqui; K L Gormly; J Bhoday; S Balyansikova; N J Battersby; M Chand; S Rao; P Tekkis; A M Abulafi; G Brown
Journal:  Clin Radiol       Date:  2016-07-02       Impact factor: 2.350

4.  Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer.

Authors:  M Chand; R I Swift; I Chau; R J Heald; P P Tekkis; G Brown
Journal:  Ann R Coll Surg Engl       Date:  2014-10       Impact factor: 1.891

5.  Transanal endoscopic surgery with total wall excision is required with rectal adenomas due to the high frequency of adenocarcinoma.

Authors:  Xavier Serra-Aracil; Aleidis Caro-Tarrago; Laura Mora-López; Alex Casalots; Pere Rebasa; Salvador Navarro-Soto
Journal:  Dis Colon Rectum       Date:  2014-07       Impact factor: 4.585

6.  Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience.

Authors:  Uday B Patel; Fiona Taylor; Lennart Blomqvist; Christopher George; Hywel Evans; Paris Tekkis; Philip Quirke; David Sebag-Montefiore; Brendan Moran; Richard Heald; Ashley Guthrie; Nicola Bees; Ian Swift; Kjell Pennert; Gina Brown
Journal:  J Clin Oncol       Date:  2011-08-29       Impact factor: 44.544

7.  Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma.

Authors:  M Jeziorska; N Y Haboubi; P F Schofield; Y Ogata; H Nagase; D E Woolley
Journal:  Int J Colorectal Dis       Date:  1994-08       Impact factor: 2.571

8.  The English national low rectal cancer development programme: key messages and future perspectives.

Authors:  B J Moran; T Holm; G Brannagan; H Chave; P Quirke; N West; G Brown; R Glynne-Jones; D Sebag-Montefiore; C Cunningham; A Z Janjua; N J Battersby; S Crane; A McMeeking
Journal:  Colorectal Dis       Date:  2014-03       Impact factor: 3.788

9.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

10.  EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy.

Authors:  M Chand; A Bhangu; A Wotherspoon; G W H Stamp; R I Swift; I Chau; P P Tekkis; G Brown
Journal:  Ann Oncol       Date:  2014-04       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.